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AB S T R A CT  
During recent years, a plethora of pioneering radiolabeled nanoparticles have grown to be an 
integral part of nuclear medicine as theranostic tools. Herein, we focus on the most 
representative examples of nanoparticles of the past decade, which have been investigated in 
conjunction with radioisotopes aiming to serve as drug delivery or imaging agents. The 
present review highlights the key attributes of each nanosystem and the following 
classification of radiolabeled nanovehicles is based on increasing mass number (A) of 
radioisotopic elements.  
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1 Introduction  
Cancer is a generic term for a large group of diseases characterized by the uncontrolled growth and spread 
of abnormal cells, caused by an interaction between external factors and mutations on a molecular level, 
both of which are yet to be fully understood. Certain types of cancer along with stroke, ischaemic heart and 
respiratory diseases are classified by the World Health Organization (WHO) in the top 5 of leading causes 
of morbidity and mortality worldwide for the year 2015 [1]. According to the last report of “Globocan 
Project” of the International Agency for Research on Cancer (IARC) of WHO, 14.1 million new cancer 
cases, 32.6 million people living with cancer and 8.2 million deaths worldwide were estimated for the year 
2012 [2]. The number of new cases is estimated to reach the staggering number of 23.97 million over the 
next 2 decades. According to deaths recorded in 2015 and by simple calculations, approximately 17 people 
per minute succumb to this devastating disease worldwide.  
In the last decades, a considerable number of scientific disciplines and especially nanomedicine have 
flourished due to the emergence of advanced novel nanomaterials. Therapeutic and diagnostic tools based 
on nanotechnology have come to bring the revolution in current medical practice and the solution to 
problems that remain still unsolved. Due to the need of dealing with medical issues, such as cancer, 
nanoparticles have gained tremendous interest. The main role of a nanocarrier is targeted delivery of a drug 
directly into the ailing area, preventing the undesired side-effects of conventional medicines and their 
uncontrolled biodistribution. Since tumors and metastases are highly heterogenous, efficacy of 
nanomedicines has significant intra-individual difference. Various surface functionalization methods have 
been devised to influence advantageous features of nanoplatforms. In some cases, nanoparticles offer the 
possibility of additional active targeting methods by conjugating a peptide or an antibody fragment, as well 
as improved therapeutic effect by combining several different methods: chemotherapy; radioisotope 
therapy (RIT); magnetic hyperthermia (MHT); photodynamic therapy (PDT); photothermal therapy (PTT). 
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Alternative methods of treatment include surgery, radiation, chemotherapy, hormone therapy, immune 
therapy, and targeted therapy. 
Radioisotopes have grown to be an integral part of the field of medical applications both for purposes of 
drug development and now diagnostic and therapeutic applications. Multivalency provides NPs with the 
required flexibility to enable the utilization of radioisotopes in novel applications. Careful construction and 
evaluation of these NP probes using nuclear imaging methods provides considerable insight into their in 
vivo fate and their prospective utility in research and clinical application. Convergence of radiolabeling with 
the cornucopia of NPs for imaging and therapy has resulted in many particles capable of multimodal 
imaging. For cancer diagnosis, the list of imaging modalities includes Magnetic Resonance Imaging (MRI), 
Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed 
Tomography (SPECT), Optical Imaging (OI) and Cerenkov Luminescence (CL). A very useful imaging 
tool for clinical oncology is also the fused form of nuclear and anatomical images from CT and SPECT 
(SPECT/CT) or PET (PET/CT) into a single device. Molecular imaging of cancer is crucial, therefore 
almost every permutation of the various imaging modalities in combination with nanoparticle carriers is 
actively investigated. Recent advances in tumor imaging technology has opened the possibility of early 
detection of the disease, resulting in a more successful way of treatment. The most recent literature is 
mentioned, providing a classification of radiolabeled nanovehicles based on increasing mass number (A) of 
radioisotopic elements.     
2 Radiolabeled Materials 
2.1 Carbon-11 
A strategy for labeling different nanoplatforms via covalent bonding with 11C, in order to develop a useful 
tool for PET and MR imaging, was reported by Sharma et al (2013). In their study, they examined 
nanoparticles appropriately functionalized with amine (-NH2) and carboxylic acid (-COOH) groups and 
more precisely iron oxide nanoparticles (IONPs), and platinum and silicon dioxide nanoparticles. It was 
proved that all functionalized nanoconstructs could bond efficiently with the radioisotope and provide 
sufficient radioactivity to perform PET imaging and biodistribution studies [3].   
2.2 Fluorine-18 
Inorganic materials like hydroxyapatite (HA) and aluminium hydroxide (Al(OH)3) have been used to 
efficiently provide labeled radiotracers with [18F]-fluoride for in vivo imaging. These radiotracers, which 
demonstrated different in vivo behavior depending on the route of administration, were monitored by PET 
imaging and showed uptake in the joints of the skeleton. Once further modified, these nanoparticles could 
lead to targeted contrast agents with lower in vivo aggregation and uptake in the RES organs [4].  
Gold nanoparticles, functionalized with peptides and bonded covalently to N-succinimidyl-4-[18F]-
fluorobenzoate ([18F]-SFB), have been synthesized. Their in vivo biodistribution was assessed and high 
accumulation in the bladder and urine, and low intestinal uptake were demonstrated. Ex vivo biodistribution 
revealed accumulation in the RES organs which could be due to the negative surface charge of the 
nanoparticles, resulting in phagocytisis by macrophages of these organs [5]. A fast and simple strategy of 
radiolabeling and coating magnetic nanoparticles was introduced by Sun Z. et al (2016). A polymer coating 
made of polyacrylic acid (PAA) and oleylamines and the chelator S-2-(4-aminobenzyl)-1,4,7-
triazacyclononane-1,4,7-triacetic acid (p-NH2-Bn-NOTA) were applied, rendering these IONPs efficient 
PET/MR imaging probes [6]. 18F-labeled dipalmitoyl [18F]-FDP liposomes were reacted with tumor tissues, 
demonstrating increased uptake. The reaction between tetrazine and trans-cyclooctenes was exploited in 
order to attain the rapid delivery of biorthogonal tetrazine radiolabeled lisposomes to tumors, in relation to 
liposomes without the tetrazine label [7].         
Labeling strategies of polymeric nanoparticles with 4-[18F]fluorobenzyl-2-bromoacetamide ([18F]FBBA) 
were investigated and based on the rationale of radiolabeling a precursor block-copolymer and then 
incorporating it as constituent element onto other polymeric nanoparticles. Three different approaches 
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were tried; two of them consisted of two different radiolabeled block-copolymers, while the third one 
utilized [18F]FBBA entrapped in the complex. All strategies included a targeting AGBBB015F (15F) peptide, 
grafted onto the NP surface. Biodistribution profiles and PET/CT imaging were evaluated in tumor-
bearing rodents, and exhibited low accumulation in the liver and renal excretion in principal [8]. A very 
recent study investigated the possibilities offered by an organosilicon fluoride acceptor (SiFA) in 
conjunction with the synthesis of polymeric core-shell nanoparticles. In this study, nanoparticles of four 
distinct sizes were synthesized, functionalized and radiolabeled using a very facile and easily repeated 
method, without additional chemical modification. The nanosystems with a hydrodynamic diameter of 
33nm exhibited the best results in EMT6 tumor-bearing mice [9].  
2.3 Copper-64 
Liposomes of various sizes were synthesized, doped with 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) which was functionalized with the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA) chelator for 64Cu labeling and evaluated as potential PET radiotracer for bone marrow imaging. 
Higher accumulation in the bone marrow was revealed for the smaller-sized liposomes in comparison to 
larger-sized ones, at 24 h post-injection. Tumor accumulation in animal models was unequivocally smaller 
than accumulation in the bone marrow [10]. Furthermore, Lee H. et al (2015) developed another method 
for 64Cu radiolabeling via the gradient loadable chelator 4-DEAP-ATSC encapsulated into PLD (liposomal 
doxorubicin (DOX) decorated with polyethylene glycol chains) and PLD targeted with HER2. In vitro as 
well as in vivo stability studies exhibited high stability up to 48h (>99%) and 24h (>94%) respectively. 
PET/CT imaging in BT474-M3 xenografts substantiated the use of these radiolabeled nanoparticles as PET 
tracers for in vivo liposome tracking [11]. A more recent study utilized DOX-loaded liposomes capable of 
PET and NIFR imaging after conjugation with 64Cu and IRDye800CW respectively. A PD-1 (programmed 
cell death-1) monoclonal antibody was also added onto this nanoconstruct, enabling 4T1 tumor 
visualization and treatment [12]. Lipid nanoparticles (LNPs), containing a distearoyl phosphatidyl 
ethanolamine monomethoxy polyethylene glycol (DSPE-PEG)-maleimide co-polymer, were assembled and 
covalently linked to an anti-prostate membrane antigen (PSMA) single chain (scFv) antibody with cysteine, 
enabling active targeting. Later on, the DOTA chelator was added to offer radiolabeling with 64Cu. Through 
this research, it was proved that scFv antibodies could be utilized as therapeutic tools due to their potential 
of conjugation with nanoparticles as they offered enhanced anti-tumor targeting [13].  
Pang B. et al (2015) designed PdCu tripods with a conformal Au shell. This well-structured platform was 
radiolabeled by substitution of some of the Cu particles of the core with the radioactive counterpart. After 
conjugation with D-Ala1-peptide T-amide (DAPTA), the tripods could serve as an efficient platform for 
PET imaging and photothermal treatment for triple negative breast cancer (TNBC) with enhanced 
anticancer properties, as proved by the in vivo results [14]. In another study, a controllable layer of gold 
nanoparticles was used to encapsulate 64Cu ions, using a chelator free process. The highly stable construct 
was studied in vivo with PET imaging in tumor-bearing animal models with three different coatings (1-
dodecanethiol and Tween 20; MeO-PEG5000-SH; and sodium 10-mercaptodecane-sulfonic acid and (10-
mercaptodecyl)trimethylammonium bromide)), resulting in PEG-coated Au nanoparticles which 
demonstrated longer circulation time and enhanced tissue uptake compared to the other two coatings 
examined [15]. Radiolabeled Au nanorods have also been used to study in vivo kinetic behavior with regard 
to their size. These nanorods are delivered to the tumorous site via the enhanced permeability and retention 
(EPR) effect [16]. Nanoclusters (NCs) have also started to be thoroughly investigated in cancer diagnostics, 
as was the case when Zhao Y. et al (2017) utilized Au NCs for breast cancer and metastasis recognition. 
Targeting of the overexpressed CXCR4 receptor and consequent PET imaging was possible after doping 
with 64Cu and functionalizing the AuNCs with plerixafor. Eventually the pharmacokinetics of these 
complexes were assessed, and high sensitivity and accuracy in early-stage tumor detection was reported [17]. 
Glycol chitosan nanoparticles (CNPs) were synthesized with a copper-free click chemistry method aiming 
to prove that such a method would facilitate a preradiolabeling pathway for the in vivo assessment of 
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radiolabeled nanoparticles. Following this synthetic pathway, a DCBO-PEG4-Lys-DOTA-64Cu complex 
was formed, where dibenzyl cyclooctyne (DBCO) was conjugated to a DOTA chelator for labeling with 
64Cu, which was then incubated with azide-functionalized CNPs, resulting in their successful radiolabeling 
at high radiochemical yields [18].    
Silica nanoparticles, functionalized with a soft electron-donating thiol group, were synthesized by Shaffer 
et al (2016) in order to achieve a thermodynamically stable bond with 64Cu without chelation and expand 
their application of silica NPs in molecular imaging using both hard and soft radiometal ions [19]. 
A common strategy for the development of radiolabeled superparamagnetic iron oxide nanoparticles 
(SPIONs) is the direct labeling of their inorganic surface with an agent that binds to its surface as well as 
with the isotope without affecting the polymeric coating. In this regard, a bisphosphonate agent was 
modified to contain dithiocarbamate and served as a chelator for the binding with 64Cu and consequent 
binding to SPIONs, namely the commercially available Endorem/Feridex. In vitro studies demonstrated 
sufficient binding for at least 48h, while PET-CT and MRI studies revealed uptake in the popliteal lymph 
nodes and the iliac lymph nodes, to a lesser extent [20]. In another study, SPIONs utilized as vehicles for 
an anticancer agent (doxorubicin) via a pH-sensitive bond were decorated with PEG chains, the cyclo(Arg-
Gly-Asp-D-Phe-Cys) peptide (c(RGDfC)) for tumor targeting and 1,4,7-triazacyclononane-N,N’,N’’-
triacetic acid (NOTA) chelator for radiolabeling. This approach resulted in a cytotoxic nanocarrier capable 
of PET and MR imaging by efficiently targeting ανβ3-expressing tumors [21]. 
Radiolabeled graphene oxide (GO) nanoparticles were exploited as imaging agents as well as drug delivery 
vehicles in breast cancer lung metastasis animal models. Radiolabeling was accomplished via a NOTA 
chelating agent, while a monoclonal antibody (mAb) was used to drive these carriers to the follicle-
stimulating hormone receptor (FSHR). DOX was sufficiently loaded to the carriers and successfully 
delivered to tumorous sites, in contrast with the untargeted NPs [22]. Manganese oxide nanoparticles 
(Mn3O4) could be useful diagnostic tools for PET and MR imaging. Similarly to the GO NPs mentioned 
above, the Mn3O4 nanoparticles were coated with PEG, labeled with 64Cu via the NOTA chelator and 
actively targeted with the addition of the TRC105 antibody. The enhanced targeting specificity of the 
nanocomplex towards 4T1 breast cancer was advocated by all the experimental results of this study [23].    
2.4 Gallium-68 
AGuIX are ultrasmall (diameter <5nm) rigid multimodal imaging platforms constituted of a polysiloxane 
matrix scaffold labeled with both gadolinium (Gd3+) and 68Ga via adequate chelators, which could serve as 
a PET/MR imaging agent. Initial work with DOTA as the chelating agent showed promising results, as 
residual activity on all untargeted tissues was extremely low. The initial encouraging results led Truillet et al 
(2015) to functionalize these NPs with chelators such as DOTAGA (1,4,7,10-tetraazacyclododecane-1-
glutaric anhydride-4,7,10-triacetic acid) [24] and NODAGA (2,2’-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-1-
yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid)) [24], [25], for improved radiolabeling. It was 
demonstrated that a single-injection with 68Ga-AGuIX@NODAGA nanoparticles could provide a dual-
modality imaging agent adequate for both PET and MRI.     
Small-sized gold nanoparticles (2nm) were coated with glucose and conjugated with the NOTA chelating 
agent for further radiolabeling with 68Ga. The aim of this nanosystem was to explore the blood brain barrier 
permeability (BBB) with PET imaging. Therefore, targeted and non-targeted systems were prepared in the 
presence or absence of BBB-permeable neuropeptides. A 3-fold higher brain accumulation of the targeted 
AuNPs was shown by the in vivo biodistribution studies [26]. Iron Oxide nanorods, coated with silica and 
various ratios of PEG and DOTA chelator were assessed as potential PET/MR imaging agents. All silica 
coated iron oxide nanorods formed highly stable radiolabeled complexes, both with and without chelator. 
Furthermore, it was shown that PEG-coated nanorods were also capable of direct radiolabeling within 15 
minutes of incubation with 68Ga, with high in vivo stability, suitable for PET/MR imaging of liver 
malignancies [27]. In the same direction, Moon S.H. et al (2016), encapsulated iron oxide nanoparticles with 
three amphiphiles containing PEG, the DOTA chelator for 68Ga radiolabeling and the prostate-specific 
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membrane antigen (PSMA) for tumor targeting. MR imaging studies resulted in uptake by only PSMA 
positive tumor cells in dual-tumor animal model, which was also confirmed by PET imaging [28]. Another 
dual-modality imaging probe was devised from the same group for the targeting of lymph nodes, with 
encapsulation of IONPs in amphiphiles containing NOTA and D-mannose, the specificity of which was 
confirmed with PET and MR imaging [29].  
Graphene oxide (GO) nanosheets were hybridized with 68Ga-magnetite (Fe3O4) NPs, forming a 
radiolabeled magnetic graphene oxide (MGO) nanocomposite that can be applied as a drug delivery system. 
No detachment of 68Ga from the complex was shown in in vitro stability studies, while in vivo biodistribution 
studies revealed high uptake by vital organs and fast clearance from the kidneys, as well as reduced NP 
uptake by the RES organs, which can be attributed to GO grafting of magnetite NPs. Consequently, 68Ga-
MGO could serve as promising agent for PET imaging [30]. In the aim of assessing porous zirconia NPs 
as drug delivery nanoplatforms, these were functionalized with the DOTA chelator and consequently 
radiolabeled with 68Ga at high radiolabeling yields. In vitro studies demonstrated a very stable radiolabeled 
complex while μPET/CT results showed higher uptake of the NPs in the RES organs, low uptake in the 
lungs indicating the lack of aggregates, extended blood retention times and slow kidney clearance [31].    
2.5 Arsenic-71, 72, 74, 76 
Although As radioisotopes are not widely used because of limited availability and difficulties related to their 
production, separation and purification of the radioisotopes [32], Chen F. et al (2013) employed a simple, 
chelator-free and efficient protocol to synthesize *As-radiolabeled SPIONs functionalized with a layer of 
oleic acid (OA) surfactant which was later replaced by poly(acrylic acid) (PAA), leading to higher stability 
of the NPs in biological solutions. Further coating with PEG made the system more stable, showing high 
liver uptake and significantly decreased bladder uptake, results also confirmed by PET imaging [33].  
2.6 Zirconium-89 
In the study of Karmani et al, gold nanoparticles with a mean size of 5nm were functionalized with the 
monoclonal antibody cetuximab, which was first radiolabeled with 89Zr via a desferal moiety. The team used 
a new method for the synthesis, compared the biodistribution before and after the coupling reaction and 
evaluated quantitive PET imaging performance of the complexes. In vitro studies showed that all conjugates 
were stable, while in vivo distribution showed no alteration in tumor uptake between the conjugated and 
unconjugated cetuximab, indicating that 89Zr-labeled cetuximab-targeted nanoparticles preserved their 
tumor targeting properties [34]. Ultra-small paramagnetic iron oxide nanoparticles (USPIOs) were 
developed to create stable and chelate-free radiolabeled complexes using a novel reaction process. 89Zr was 
bound to the surface of the magnetite core, through ionic interactions of the opposite charges between the 
metal ions and the surface layer, resulting in radiolabeling yields over 90%. PET/CT imaging studies were 
performed, confirming the ability of these nanoplatforms to be radiolabeled with other radioisotopes (i.e. 
64Cu2+, 89Zr4+, 111In3+) under the same radiolabeling conditions [35]. In another study, ferumoxytol was 
linked to the desferrioxamine chelate (DFO) and radiolabeled with 89Zr, in order to acquire a tool that could 
combine PET and MR imaging for the enhanced detection of lymphatic drainage [36].   
Imaging of the lymphatic drainage with PET and MRI was also the objective of a recent study, where metal 
oxide (MxOy) nanoplatforms were coated with PEG and radiolabeled with a chelator-free process. They 
developed constructs with 10 different types of MxOy and selected the gadolinium (Gd) containing 
nanoplatform for further testing [37]. Nanoscale metal-organic frameworks (nMOF) materials were 
investigated as drug delivery vehicles capable of fluorescent and PET imaging for negative breast neoplasia. 
These octahedron-shaped nanocarriers were labeled with 89Zr, decorated with pyrene-derived polyethylene 
glycol (Py-PGA-PEG) chains, actively targeted with F3 ligand and loaded with DOX. The results were 
encouraging as there was no toxicity referred to the experimental murine models [38].  
A chelator-free system of radiolabeled mesoporous silica nanoparticles (MSN) was presented attaining a 
long-term in vivo stability of more than 20 days. Both radiolabeling and in vivo stability appeared to be 
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interwoven with the presence of deprotonated silanol groups (-Si-O-) inside or on the surface of the 
nanoparticles. The conclusion of this study was that 89Zr-MSN could be a useful tool for tracking the in vivo 
fate and PET imaging of drug delivery systems [39]. Yet another 89Zr PET tracer was developed by 
radiolabeling ultrasmall fluorescent silica nanoparticles (C dots) using two pathways: a chelator-free 
radiolabeling method and a DFO chelating agent. Both nanoplatforms had an integrin-targeting peptide 
(cRGDY) attached and were coated with PEG. Their stability, pharmacokinetics and uptake were 
investigated in human melanoma models with encouraging results [36].       
Liposomal nanoparticles were developed and efficiently radiolabeled with 89Zr using a ligand exchange 
reaction. Three versatile vehicles encapsulating desferrioxamine (DFO) were produced, all with high 
radiochemical yields, one of which was PEGylated while the other one was actively targeted with the aid of 
folic acid (FA). Comparative studies pertaining to their stability, cell uptake and in vivo pharmacokinetics 
were performed [40]. 
Truillet et al (2016) described the synthesis of AGuIX nanoparticles functionalized with DFO, which were 
radiolabeled with 89Zr at high yields (~99% yield), in order to evaluate the magnitude and pharmacokinetics 
of the long-lived radioisotope within the tumor microenvironment through in vitro, in vivo and PET imaging 
studies [41].  The group of Groult H. et al (2015) performed very extensive research pertaining to the facile 
functionalization of 3 different types of nanoparticles, using a modular approach and exploiting the high 
versatile and binding capabilities of bovine serum albumin (BSA). IONPs, upconverting nanophosphors 
and Au nanospheres were used in this study in conjunction with various chelating agents appropriate for 
the conjugation either with 68Ga or 89Zr. Finally, the IONPs functionalized with BSA and modified with 
DFO were the chosen platform for further investigation. This nanoconstruct was then conjugated to RGD 
peptide and labeled with 89Zr to offer PET/CT and MR imaging capabilities [42].  
2.7 Yttrium-90 
For therapeutic purposes, 90Y was used to radiolabel magnetic (Fe3O4) nanoparticles with or without a 
poly(ethylene glycol) 600 diacid coating. The PEG-coated nanoparticles exhibited excellent in vitro stability 
and lower uptake in the lungs compared to the naked magnetic nanoparticles. The latter could be attributed 
to the presence of poly(ethylene glycol), which is an inhibitory factor of agglomeration of MNPs in vivo [43].  
Magnetic microspheres, coated with citric acid and encapsulated with human serum albumin were produced 
for application in bimodal radioisotope and hyperthermia cancer treatment. These nanoplatforms were 
radiolabeled with 90Y using a chelator-free protocol, and provided high in vitro stability and sufficient heating 
efficiency in order to induce cell apoptosis [44]. 
2.8 Technetium-99m 
Curcumin-loaded solid lipid nanoparticles were used to circumvent the low solubility and consequently the 
low bioavailability of curcumin, which is of particular value due to its anti-oxidant and anti-carcinogenic 
properties. Liver-spleen imaging with this nanosystem was found to be advantageous and potentially 
therapeutic [45]. Lipid nanocarriers were also developed by Ucar E. et al (2016), who loaded them with 
paclitaxel (PTX) and radiolabeled them using the 99mTc(CO)3+ moiety. Active targeting of folate-expressing 
tumors was efficiently achieved by surface modification with a folate derivative, as proved by the in vivo 
animal studies [46].    
Almost a decade ago, poly(lactic-co-glycolic acid) (PLGA-based nanoparticles labeled with 99mTc in a direct 
approach were developed, in order to cross the Blood Brain Barrier (BBB). These constructs showed 
promising results when loaded with chloramphenicol (CHL) and decorated with polysorbate-80 (PS-80) 
surfactant, as uptake in the brain was higher than that in the bone marrow [47]. The group of Subramanian 
et al (2010) directly radiolabeled PLGA nanoparticles, utilizing SnCl2 as the reducing agent, and investigated 
their application in sentinel lymph node detection (SLND), showing localization in the SLN, albeit lower 
than the uptake observed for the commercially available for SLN detection radiopharmaceutical Nanocis 
[48]. A few years later, the same group utilized the PLGA nanoparticles mentioned above in two different 
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ways, one by encapsulating mebrofenin in situ and another by conjugating p-aminobenzyl diethylenetriamine 
pentaacetic acid (p-NH2-Bz-DTPA). The latter functionalization led to improved radiolabeling yields under 
milder reaction conditions and improved uptake in the SLN [49]. A common palliative treatment for bone 
metastasis with satisfactory results is the use of ethylenediamine-tetramethylenephosphonic acid (EDTMP) 
labeled with the radioisotope 153Sm. The conjugation of this acid with polymeric nanoparticles consisting 
of polylactic acid (PLA) and polyvinyl alcohol (PVA) was designed in an attempt to overcome the 
drawbacks of 153Sm-EDTMP. Indeed, biodistribution analyses conducted on these nanoparticles, after their 
radiolabeling with 99mTc, came to prove this theory, as increased accumulation of these 99mTc-
PLA/PVA/EDTMP complexes in osseous tissues was observed [50]. 
Gold nanoparticles were also developed as potential SLN imaging agents which remained within the first 
lymph node for 24h, with negligible uptake in all other tissues and minimal accumulation in the kidney [51]. 
This was pursued by conjugating Au nanoparticles to the hydrazinonicotinamide-Gly-Gly-Cys-NH2 
(HYNIC-GGC) peptide, a thiol-triazole-mannose derivative and EDDA/tricine coligand. Furthermore, in 
order to achieve GRP-r imaging, gold NPs were functionalized with Lys3-bombesin and radiolabeled with 
99mTc. Biodistribution studies showed maximum tumor uptake of the radiotracer at 1h post-injection [52]. 
The above results encouraged Ocampo-Garcia et al (2011) to formulate a kit for facile labeling of AuNPs 
conjugated to Lys3-bombesin, cyclo[Arg-Gly-Asp-D-Phe-Lys-(Cys)] or thiol-mannose, which is important 
as the development of such kits could be a useful tool for the preparation of radiolabeled NPs used for 
target-specific applications in the clinic [53]. The most recent study on Au nanoparticles radiolabeled with 
99mTc radioisotope was conducted by Zhao L. et al (2018), who entrapped the nanoparticles in 
polyethylenimine (PEI) so as to obtain a dual-modality imaging probe. PEI offered versatility for further 
conjugation with the DTPA chelator and a PEG monomethyl ether, aiming to improve the properties of 
the nanoconstruct, namely stability, biocompatibility and imaging performance in SPECT/CT imaging of 
lymph nodes and other organs [54].  
Ultra-small paramagnetic iron oxide nanoparticles were prepared along with a PEG polymer conjugate 
containing a terminal 1,1-bisphosphonate (BP) group, resulting in stealth and stable nanoparticles with 
enhanced properties. In vivo studies revealed a strong T1-effect, making them effective as MRI contrast 
agents at high magnetic fields, as well as SPECT imaging due to 99mTc, rendering them suitable agents for 
multimodal imaging [55]. For the same purpose, SPIONs were coated with dextran and radiolabeled with 
99mTc using SnCl2 as the reducing agent. The effect of different modes of administration (intravenous or 
intra-arterial) as well as the localization of the tumor sites with or without the addition of Lipiodol, were 
investigated. Finally, intra-arterially delivered complexes with Lipiodol demonstrated enhanced results 
against liver tumor [56]. Another dual-modality imaging agent was developed from radiolabeling iron oxide 
nanoparticles linked to cRGDfK-Orn3-CGG (an RGD peptide derivative) and functionalized with 3-
aminopropyltriethoxysilane (APTES), for targeting U87MG glioblastoma cells in animal models. The 
radiolabeled construct was proved to be a highly stable complex in vitro, which had the ability to reach 
satisfying ablative temperatures in vivo. These RGD-targeted nanoparticles demonstrated enhanced 
accumulation in tumor sites with negligible accumulation in other organs [57]. The properties of magnetic 
and gold nanoparticles, once combined, could lead to enhanced dual-modality probes. This was the basic 
idea behind the work of Felber et al (2015), who developed gold containing magnetite (Fe3O4) nanoparticles. 
The metal surface consisted of an anchor for Au, bifunctional ligands and chelating agents for the 
[99mTc(CO)3]+ moiety. The synthesis was approached in two different pathways, both of which showed 
promising results [58]. 
Silica nanoparticles could prove to be an efficient platform both for dual-imaging applications and targeted 
delivery of anti-tumor agents. This type of nanosystem was developed when polyamidoamine (PAMAM) 
was grafted onto silica nanoparticles, which were thereafter conjugated with fluorescent dye (indocyanine 
green (ICG)), loaded with 99mTc and functionalized with an anti-HER2 antibody, which provided sufficient 
targeting capabilities as shown by in vitro and in vivo studies [59]. An effort was made to develop 
radiolabeled mesoporous silica nanoparticles (MSNs) as imaging agents, with the functionalization of the 
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nanoparticles with 3-aminopropyltriethoxysilane (APTES) and diethylenetriaminepentaacetic acid (DTPA). 
Results demonstrated the expected high uptake by liver and especially high specificity for the lung. Given 
the fact that MSNs are able to carry a significant drug load at the same time, they could also be potential 
theranostic agents [60]. A structure consisting of manganese oxide (MnOx) within the mesopores of MSNs, 
which was also loaded with doxorubicin, was designed and evaluated as a probe for both hybrid SPECT-
MR imaging but also as a therapeutic tool [61].  In another study based on MSNs, two strategies were tested. 
In the first strategy, safranin O was loaded onto the pores of the nanoparticles and the MSNs were 
functionalized with APTES. Then they proceeded to the addition of MUC1 aptamer, which enables 
targeted delivery to MDA-MB-231 cells. The second strategy was on the same track as the one mentioned 
before, only doxorubicin was used instead of safranin O, with considerably increased cytotoxic effects. The 
safranin O loaded complexes, were also radiolabeled with 99mTc demonstrating enhanced specificity and 
internalization, after intraocular administration in MDA-MB-231 tumor-bearing mice [62].  
Liposomes radiolabeled with diagnostic radioisotopes can be excellent tools for studying the 
pharmacokinetics of liposome-based drug delivery systems, as was the case with liposomes labeled with 
99mTc(I)(CO)3. Radiolabeling techniques and their effect on the biodistribution were explored, namely direct 
labeling via a carboxyl group and chelation via a pyridyl ethyl cysteine compound. It was shown that both 
systems exhibited passive tumor accumulation [63]. 
Self-assembled nanoparticles were prepared with chitosan and folated poly-γ-glutamic acid and directly 
labeled with 99mTc. In vitro results showed efficient internalization by tumor cells while in vivo studies revealed 
improved uptake in the tumorous kidney when compared to the normal one, as well as enhanced contrast 
in SPECT and SPECT/CT tumor imaging [64]. Dendrimers were synthesized, functionalized with folic 
acid and radiolabeled with 99mTc via a chelating agent by Zhang et al (2010) with a radiochemical yield up 
to 98.9%, excellent in vitro and in vivo stability, rapid blood clearance and specific tumor accumulation [65]. 
The same group next reported on the synthesis of a dendrimer initially reacting with biotin, which was 
further reacted with avidin. Both resulting species were efficiently radiolabeled with 99mTc and 
comparatively evaluated in vitro in HeLa cells. As the cellular uptake was much higher for the avidin 
conjugate, consequent in vitro and in vivo were performed only for this construct [66].     
Generation 2 (G2) PAMAM dendrimer-entrapped gold nanoparticles, radiolabeled via chelation and 
modified with folic acid (FA) or RGD peptide, were devised by Li et al (2016) and Xu X. et al (2017) 
respectively [67], [68]. The chelating agents used in each study were the linear chelate DTPA and and the 
cyclic chelate NOTA, which were conjugated onto the surface of the dendrimers, enabling 99mTc to bind, 
thus rendering both nanoprobes suitable for SPECT and CT imaging. 
2.9 Indium-111 
In a facile and robust method developed by Laan et al (2016), tropolone and 111In were entrapped in the 
core of micelles, without the surface conjugation of the chelator that might lead to altered biological 
behavior and compromised stability. Ex vivo biodistribution studies in healthy mice demonstrated high liver 
and spleen accumulation and significant blood circulation even at 24h post-injection [69]. Micelles cross-
linked with pluronic unimers and more specifically poly(ethylene oxide) and poly(propylene oxide) (PEO-
PPO-PEO), and radiolabeled with 111In via DTPA, were studied with respect to in vivo biodistribution using 
SPECT. The effecr of PEO block length on renal clearance and overall liver uptake, as well as the influence 
of the aggregation state on long term accumulation in the liver, were investigated [70].   
Gold nanoparticles have been used for the molecular targeting of low- and high-ανβ3 integrin-expressing 
tumors. Although the radiolabeling with 111In was achieved without surface functionalization with metal 
chelators, biodistribution and imaging studies demonstrated a stable radiolabeled nanoparticle [71]. The 
tumoricidal properties of gold nanoparticles after coating with PEG, further linked to trastuzumab and 
111In via DTPA chelation, were investigated. Intratumoral administration in overexpressing HER2-positive 
breast cancer animal models demonstrated efficient internalization, halting tumor growth as well as inducing 
DNA double strand breaks (DSB), thereby reducing the surviving fraction of cancer cells [72]. Song L. et al 
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(2016) proposed an easy protocol to radiolabel Au nanoparticles targeting epidermal growth factor receptor 
(EGFR) positive tumors 111In with via the DTPA chelator [73].  
Superparamagnetic iron oxide nanoparticles were used for the development of bioprobes for early diagnosis 
of cancer. Conjugation with 111In-labeled antimesothelin antibody mAbMB provided the SPIONs with the 
capacity to localize and image mesothelin-expressing cancer cells with both SPECT and MR imaging 
modalities [74]. Zolata H. et al (2015) decorated the surface of SPIONs with APTES, PEG and then 
conjugated thiolated bifunctional chelator 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-
3,6,9,-triacetic acid (PCTA). Furthermore, the nanoplatform was actively targeted with the monoclonal 
antibody trastuzumab, and drug-loaded with doxorubicin. Further studies proved their accumulation in 
tumors due to the EPR effect and HER2 receptor targeting, as well as their efficacy as therapeutic agents 
in breast cancer animal models [75]. In order to exploit the advantages provided by triple-modal imaging, 
Bai J. et al (2016) designed magnetic nanocapsules (NCs) loaded with hydrophobic SPIONs. These spherical 
NCs were shown to be capable of fluorescent imaging (by using indocyanine green), MRI (due to the 
SPIONs) as well as nuclear imaging (due to 111In labeling). Studies performed in tumor-bearing mice 
demonstrated increased tumor uptake after application of an external magnet at the tumor area, in 
comparison to NCs delivery to the tumor site via EPR [76].   
A copolymer consisting of poly(lactic acid) (PLA) and PEG, radiolabeled with 111In was investigated by 
Banerjee S.R et al (2017). SPECT and Near-infrared fluorescence (NIFR) imaging were used to reveal its 
pharmacokinetics and biodistribution, providing a direct comparison between the PSMA-targeted and the 
non-targeted complex. Similar accumulation in all tissues was demonstrated by both complexes except in 
tumor and liver, where they demonstrated different uptake and stability results. Microscopy studies showed 
that accumulation of the non- PSMA-targeted nanoparticles was less epithelium-specific, and dependent 
on an EPR and phagocytosis combination [77]. 
2.10 Iodine-125, 131 
A method that enables rapid radiolabeling with 125I of silver nanoparticles capable of tracking the in vivo 
tissue uptake after their systemic administration, was developed by Chrastina A. and Schnitzer J.E. (2010). 
Nanoparticles were labeled via chemisorption of 125I onto the Ag surface and administered intravenously. 
Biodistribution studies and SPECT imaging demonstrated high uptake and accumulation in the liver and 
spleen, something that should be investigated as it could lead to potential toxicity issues [78]. Seven years 
later, another simple and concomitantly efficient method was introduced for radiolabeling three types of 
Ag nanoparticles; pure Ag, a polyvidone (PVP)-Ag complex and a doxorubicin-PVP-Ag NP conjugate. 
Biodistribution studies revealed higher uptake in cancerous cells for the latter nanocomplex, rendering it as 
a promising theranostic agent [79]. 
A dual-modality imaging agent applicable in SPECT and MRI was developed by modifying USPIOs with 
an RGD peptidex. Radiolabeled nanoparticles with high radiochemical purity, stability and tumor specificity 
were produced, with biodistribution and in vivo studies verifying the promising abilities of these 
nanoconstructs as radiotracers of ανβ3-overexpressing tumors. Replacement of 125I with 123/124I or 131I could 
provide a PET radiotracer or therapeutic agent, respectively [80]. Another similar agent was constructed by 
Wang J. et al (2016) who conjugated 125I-c(RGDyK) peptide onto magnetic nanoparticles that had first been 
coated with PEG. This construct targeted U87MG tumors in murine models, which were in turn treated 
with photothermal therapy in vivo. SPECT/MR imaging modalities confirmed low mononuclear phagocyte 
uptake [81]. Radiolabeled hydroxyapatite (HAp) nanoparticles with and without further modification were 
investigated, pertaining to their capability as organ-targeting carriers. The nanosystems evaluated were 
radiolabeled with 125I and consisted of HAp nanoparticles, HAp modified with chitosan (Ch) and HAp 
nanoparticles with a coating of blended Ch with poly-D,L-lactide-co-glycolide polymer (PLGA). The 
stability, kinetics and targeting behavior of these three constructs were evaluated in vitro and in vivo, and 
demonstrated significant differences from one group of nanoparticles to the other, with both the chitosan 
coated nanoparticles exhibiting elevated radioactivity in various organs [82].   
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Recently, Clanton R. et al (2018), exploited the strong interactions developed between gold and iodine 
atoms, and proceeded to synthesize Au nanocarriers with radioactive 125I integrated into their structure. 
The timing of 125I addition was investigated, as it is blamed for the aggregation that occurs when it is added 
too early in the synthetic process. As AuNPs target neoplastic cells with increased energy consumption, 
these stable 125I-labeled AuNPs show great potential as theranostic agents (x-ray/CT imaging due to the 
AuNPs and therapy due to 125I  [83].  A variety of metal-organic complexes was investigated, focusing 
especially on Cobalt (Co) nanotubes (NTs) functionalized with folic acid. Doxorubicin was embedded in 
these targeted nanocarriers which were traceable in murine models with the aid of 131I. Tumor growth was 
found to be suspended in vivo, with minimal side effects reported [84]. 
A self-assembled amphiphilic, protein-based conjugate comprised of hydrophobic maleimide-
functionalized poly-(ε-caprolactone) (PCL) covalently linked to hydrophilic bovine serum albumin (BSA), 
was directly labeled with 131I. After its synthesis, the BSA-PCL conjugate was functionalized with anti-
epidermal growth factor receptor (anti-EGFR) antibody and utilized for targeted RIT. The anti-EGFR-
labeled particles exhibited higher cytotoxicity in vitro and in vivo, and higher cellular and tumor uptake in 
murine cancer models, when compared to particles without the antibody [85]. In a similar rationale, 
PEGylated liposomes linked to PCL-BSA, functionalized with an RGD peptide and labeled with131I, were 
tested against lung cancer in NCI-H460 tumor-bearing mice, and showed great potential as cancer 
theranostic agents [86].    
PAMAM dendrimers were synthesized, linked to HMPAO (chelator), and conjugated with Buthus 
martensii Karsch chlorotoxin (BmK CT) as a potential theranostic tool for glioma. Although non-
radiolabeled dendrimers showed no inhibition effect on C6 glioma cells, 131I-dendrimers attained a 
significant decrease in the cancerous cell population [87]. Polypyrrole (PPy) nanoparticles, actively targeted 
with transferrin and pre-labeled with 131I were synthesized using a one-step strategy for synergistic 
anticancer treatment, combining RIT and photothermal therapy (PTT). The biodistribution, in vivo 
specificity and therapeutic efficacy of these transferrin capped nanoparticles was compared to PPy@BSA-
131I, and exhibited enhanced therapeutic response after being intravenously injected in U87MG tumor-
bearing mice [88].  
2.11 Samarium-153 
A dual-modality imaging probe, capable of upconversion luminescence (UCL) and SPECT imaging was 
designed using lanthanide-based upconversion nanophosphors (UCNPs). The objective of the study was 
the development of a post-labeling method of the interior of these nanoparticles with 153Sm. It was shown 
that this post-labeling approach could be applicable to most of the rare earth nanoparticles for their in vivo 
tracking [89]. The same type of nanoparticles was studied by Cao T. et al (2013), who modified NaYF4 
nanoparticles with PEG and co-doped them with Yb3+, Er3+ and 153Sm3+. The ultrasmall radiolabeled 
nanoparticles (<10nm) exhibited renal clearance and dual-modality imaging capabilities via γ-counter 
analysis and SPECT [90]. 
Hydroxyapatite nanorods (HA) incorporated with gadolinium (Gd) were post-labeled with radioactive 
samarium, and their biodistribution was studied. These nanosystems proved to accumulate in the liver and 
spleen and demonstrated difficulty in excretion from the latter. However, 153Sm-HA:Gd showed enhanced 
properties in vitro and imaging abilities with both SPECT and MR imaging in vivo [91].  
Another SPECT/MR imaging probe was suggested by Gholami A. and Mousavie Anijdan S.H. (2015) who 
synthesized SPIONs and radiolabeled them with 153Sm via a DTPA dianhydride chelating agent. 
Biodistribution studies showed high uptake in the reticuloendothelial system (RES) while exhibiting rapid 
clearance from blood and other organs. Therefore, these nanoconstructs could unambiguously be 
considered as a useful tool in RES theranostics [92]. Samarium oxide-152 ([152Sm]Sm2O3) was encapsulated 
in PLGA nanoparticles and activated in a nuclear reactor, thus producing radioactive [152Sm]Sm2O3-PLGA 
NPs. A tracer kinetics study was conducted in rats, to determine the effects of different modes of 
administration. In the case of intravenous administration, the NPs were rapidly accumulated in the RES 
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organs, while in the case of oral administration low-dose distribution to most organs was confirmed, 
indicating absorption of the nanoconstructs [93].    
2.12 Holmium-166 
The theranostic capabilities of 166Ho, a β- and γ- emitting isotope, were exploited when it was mixed with 
SPIONs functionalized with the DTPA chelator. A product of high radiochemical purity was provided, 
with accumulation in the liver and spleen, proving the efficacy of these nanoconstructs as RES theranostic 
agents [94]. A different approach for 166Ho radiolabeling was developed by Di Pasqua A.J. et al (2012) who 
used stable Holmium-155 in conjunction with mesoporous silica MCM-41 nanoparticles, and irradiated the 
system, thus producing a radioactive complex. This complex was tested in murine models with orthotopic 
non-small cell lung cancer, giving satisfactory results [95].   As mentioned in the example above, irradiation 
of a complex containing 165Ho in order to acquire a radiolabeled with 166Ho carrier is a common strategy. 
Based on this strategy, mesoporous carbon nanoparticles (MCNs) that contain holmium oxide were 
neutron-activated to produce 166Ho-MCNs. Consequent pegylation provided a biocompatible and readily-
dispersible nanoconstruct. Toxicity studies substantiated the non-toxicity of the 165Ho-complex towards 
the cancerous cells and the exact contrary effect of the radiolabeled counterpart [96].  
In another study, holmium acetylacetonate was irradiated as described above, thus yielding a 166Ho-labeled 
nanodevice with sufficient radiation for nuclear imaging and radioablation of tumor sites via intratumoral 
injections. The great advantage of using Holmium as a contrast agent is the fact that it is a nuclide that can 
be used in MR, CT and SPECT imaging, as well as in therapeutic applications [97]. 
2.13 Lutetium-177 
A comparative study of 177Lu labeled agents was conducted by Vilchis-Juárez A. et al, who assessed the 
therapeutic response of 3 different complexes. The first complex consisted of radiolabeled gold 
nanoparticles, the second one of a radiolabeled cyclo-RGDfK(C) peptide and the last one a combination 
of the above. Radiolabeling of all three constructs was afforded via the DOTA chelator. The 177Lu-AuNP-
RGD nanoconstruct proved to be the most effective agent, demonstrating the highest uptake and retention 
in tumor cells, thus rendering it as a potential theranostic tool [98]. In another study, the stability of AuNPs 
modified with metal-chelating polymers (MCP) that embody DOTA chelators was tested. The conjugation 
of gold nanoparticles to MCP was afforded via a single thiol, a dithiol and a multi-thiol end group and their 
stability and cell uptake was evaluated [99]. The same group of Yook S. et al (2016) developed gold 
nanoseeds modified with PEG, radiolabeled via DOTA chelating agent and labeled with panitumumab that 
actively targets EGFRs, for the treatment of locally advanced breast cancer (LABC). The targeting 
specificity of the system was compared to the same non-targeted nanoseeds and the nanoconstructs were 
injected intratumorously exhibiting high radiation doses absorbed by the tumor site compared to low uptake 
in normal organs [100]. With the same rationale, trastuzumab-labeled nanocarriers were studied 
demonstrating enhanced tumor inhibition and DNA double strand breaks (DSBs) in SK-BR-3 and MDA-
MB-361 cancer cells, when compared to the unlabeled counterparts [101]. In yet another study, Au 
nanoparticles were radiolabeled with 177Lu via the DOTA-Gly-Gly-Cys (DOTA-GGC) oligopeptide. These 
NPs were surface-functionalized with an RGD peptide and a HS-pentyl-pegaptanib aptamer, and exhibited 
efficient in vitro angiogenesis inhibition in the human umbilical vein cell line EA.hy926 [102].      
A nanoprobe, comprised of gold nanoparticles in the cavity of PAMAM-G4 dendrimers was designed for 
simultaneous OI, plasmonic-PTT and targeted RIT. Bombesin and folic acid were covalently conjugated 
onto the dendrimers via their carboxylate groups, and were consequently radiolabeled with 177Lu, via the 
chelator S-2-[4-Isothiocyanatobenzyl]-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-benzyl-
DOTA). Results of T47D tumor cells treated with this complex showed an outstanding decrease in cell 
viability up to 90% [103].        
A combo treatment of breast and pancreatic cancer was devised, consisting of two separate systems; an 
anticancer agent called cyclopamine (CPA) combined with liquid-lipid nanoparticles (LLP) and radiolabeled 
49 
 
Available online at Journals.aijr.in 
Radiolabeled Nanoparticles in Nuclear Oncology 
core-crosslinked polymeric micelles (CCPM). This system was proved to limit 4T1 cancer cells and inhibited 
tumor relapse in Miapaca-2 cell lines [104]. Satterlee A.B. et al (2015) efficiently encapsulated 177Lu into 
lipid-calcium-phosphate (LCP) nanoparticles and studied the effect of increased radioisotope on the 
properties of the nanosystem. The theranostic properties of this radioisotope resulted in tumor remission 
in H460 and UMUC3/3T3 murine animal models, which could be visualized by SPECT and Cerenkov 
imaging [105].  
177Lu-DOTATATE was encapsulated in PLGA nanoparticles coated with PEG, and were assessed 
regarding their pharmacokinetics and encapsulation efficacy in vitro as well as in rats in vivo. The aim of this 
study was to evaluate the behavior of this nanosystem as a potential peptide receptor radioisotope 
therapeutic (PRRT) agent [106]. Fullerene cages have also been reported as appropriate nanovehicles for 
radioisotope therapy by incorporating 177Lu. Conjugation with interleukin-13 (IL-13) peptide dyed with 
tetramethyl-6-carboxyrhodamine (TAMRA) was also attained, giving the possibility for targeting and 
imaging of glioblastoma multiforme tumors [107].      
2.14 Rhenium-186, 188 
Due to previous indications that liposomes could improve the properties of radioactive isotopes 
incorporated, Chen M. et al (2010) further investigated this hypothesis by producing liposomes radiolabeled 
with 188Re-N,N-bis(2-mercaptoethyl)-N’,N’-diethylenediamine (BMEDA) and intravenously administering 
them in HT-29 colorectal adenocarcinoma animal models. The study of this group compared the 
biodistribution and imaging profiles of these liposomes with and without doxorubicin. Pharmacokinetic 
and bioavailability studies demonstrated similar results between the two types of liposome, which were 
superior to 188Re-BMEDA [108]. The following year, 188Re-BMEDA was encapsulated into liposomes, 
decorated with PEG and tested as a theranostic agent against brain glioma in rat models. Autoradiography, 
histopathological analysis and SPECT/CT imaging showed potential of this nanoconstruct and set the path 
for further investigation [109]. A study focusing on brachytherapy of glioblastoma followed, in which 
liposomes were used, this time with rhenium-186 radiolabeling. Due to the short path length of 186Re, the 
behavior of this nanoconstruct was monitored with SPECT/CT imaging and gamma camera after 
radiolabeling with 99mTc. Results showed no overt toxicity of surrounding tissues even at high doses [110].    
Aptes-functionalized SPIO nanoparticles were modified with the N-hydroxysuccinimide (NHS) ester of 
polyethylene glycol maleimide (NHS-PEG-Mal). An N2S4 chelating agent was conjugated to the surface of 
the modified SPIONs for further radiolabeling with 188Re. The therapeutic and targeting efficiency of this 
complex was studied for both the targeted (with the addition of Rituximab) and untargeted system (for 
accumulation through the EPR effect). Results showed efficient tumoricidal effect of the targeted SPIONs 
[111].   
Modification of graphene oxide nanoparticles with silica-coated, core-shell magnetic nanoparticles was 
attained, aiming to manufacture a peanut-shaped platform, which is supposedly more easily taken up by 
tumorous tissue, when compared to the spherical counterpart. These nanovehicles were loaded with 
gambogic acid, while polyethyleneimine (PEI) was also grafted onto their surface. Radiolabeling with 188Re 
offered the possibility of internal radiotherapy in VX-2 tumor animal models, with simultaneous SPECT 
and CT imaging [112]. 
2.15 Gold-198 
A decade ago, gold and dendrimer composite nanodevices (CNDs) were synthesized and radiolabeled, 
resulting in a poly{198Au0} CND system targeting melanoma tumors which exhibited up to 45% regression 
in murine models [113]. A couple of years later, gold nanoparticles labeled with 198Au and functionalized 
with gum arabic glycoprotein (GA) were administered intratumorally and studied in vivo, demonstrating high 
tumor affinity in human prostate tumor-bearing mice. Clinical studies showed surpassing tumor volume 
reduction up to 82% comparing to the control group, and pharmacokinetics of the nanosystem 
substantiated minimal or no leakage of radioactivity to the non-targeted organs [114]. On the same pathway, 
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gold nanoparticles were also functionalized with epigallocatechin-gallate (EGCg) and radiolabeled in order 
exploit the strong antioxidant properties of EGCg. Besides its antioxidant properties, EGCg targets the 
laminin receptor Lam67R, which is overexpressed on human prostate cancer cells, resulting in similar tumor 
volume reduction as mentioned above [115]. Since studies with 198Au focus on gold nanoparticles, a 
comparison study of similar-sized but differently shaped (spheres, disks, rods, cages) PEGylated gold 
nanoparticles was conducted in EMT6 tumors. The results of this study demonstrated enhanced 
accumulation of the nanospheres and nanodisks in tumorous sites albeit on the surface, when compared to 
nanorods and nanocages which presented a lower accumulation but better intratumoral distribution [116].  
The nascent possibilities of 198Au-doped gold nanocages were reported by Wang Y. et al (2013), who 
demonstrated the unprecedented Cerenkov luminescent capabilities of the radioisotope. The radiolabeled 
nanostructures were decorated with PEG chains and offered luminescent imaging of EMT-6 tumors after 
intravenous administration in murine animal models [117].  In an effort to incorporate radioisotopic 199Au 
in Au NPs, Zhao Y. et al (2016) once again used gold nanoparticles as nanocarriers. PEGylation and linking 
to DAPTA followed, in order to provide efficient imaging via SPECT of a triple negative breast cancer 
(TNBC) and its metastasis [118].  
2.16 Bismuth-213 
A liposomal carrier for 213Bi was designed by Lingappa M. et al (2010), who functionalized the liposome 
with DTPA for radiolabeling, and with a mouse anti-Her/neu monoclonal antibody for targeted treatment 
of metastatic mammary carcinoma. The targeted liposomal vehicle, when compared to the same construct 
without the antibody and to the radiolabeled antibody without the liposome, showed increased cytotoxicity 
when compared to the non-targeted construct, and less efficacy when compared to the radiolabeled 
antibody [119].  
2.17 Radium-223,225 
With alpha decay nanoparticles, a major challenge is faced, namely the inability of traditional chelating 
agents to retain the radioactive daughters of the parent radioisotope at the targeting site without damaging 
adjacent tissue. For this purpose, core lanthanum phosphate and core-shell (with up to two shells) 
nanoparticles were evaluated pertaining to their capability to retain 223Ra and 225Ra/225Ac isotopes, and were 
shown to exhibit satisfactory retention abilities as radioisotope nanocarriers [120]. 
Mokhodoeva et al investigated the direct labeling of SPIONs with 223Ra, the first alpha-emitting radioisotope 
with FDA approval for clinical application. It was demonstrated that the [223Ra]Fe3O4 NPs retained their 
radiolabel for up to 24 h post-preparation, while in vitro stability studies in PBS, bovine plasma and serum 
at 11.4 and 22.8 days showed a maximum average 223Ra release of 5%, rendering these NPs suitable for 
further in vivo testing [121].  The group of Piotrowska A. et al (2017) utilized type A nanozeolite nanoparticles 
containing sodium, which were linked to an NK-1 receptor-targeting peptide. These NPs were pegylated 
and labeled with 223Ra by ion exchange with the sodium. Results showed efficient targeting of glioma cells 
and satisfactory retention of the radioisotope in the NPs [122]. 
2.18 Actinium-225 
A multi-shell nanosystem consisting of lanthanide phosphate core-covered with a gold shell and four 
additional shells of gadolinium phosphate was devised in order to overcome the difficulties reported on 
targeted alpha therapy (TAT) [123]. The same group proceeded to further functionalize these nanoparticles 
with the monoclonal antibody 201b via the carboxylate group of discrete polyethylene glycol chains. 
Tumor-eradication properties of the nanoconstruct were demonstrated, with the daughter isotope 213Bi 
being retained by the nanoparticles in the lung up to ~90% at 24h post-injection [124]. 
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3 Conclusions 
Despite the numerous successful studies of radiolabeled nanoparticles applied in adjuvant therapy, work in 
this field is still in its infancy and there is a need for research that performs in-depth investigation on real 
diagnostic or therapeutic applications with potential for clinical translation. It is expected that improved 
NPs will be developed, based on the accumulated knowledge and technology in which radioisotopes 
promise to continue playing an important role. We hope that these multifunctional NPs for multimodal 
imaging and theranostics can overcome present challenges and provide great contributions to human health 
in the near future. 
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